{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "16532723",
  "DateCompleted": {
    "Year": "2006",
    "Month": "04",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2007",
    "Month": "11",
    "Day": "15"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "ita"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1827-6806",
      "JournalIssue": {
        "Volume": "7",
        "Issue": "2",
        "PubDate": {
          "Year": "2006",
          "Month": "Feb"
        }
      },
      "Title": "Giornale italiano di cardiologia (2006)",
      "ISOAbbreviation": "G Ital Cardiol (Rome)"
    },
    "ArticleTitle": "[Heart rate: a cardiovascular risk factor that can no longer be ignored].",
    "Pagination": {
      "StartPage": "119",
      "EndPage": "128",
      "MedlinePgn": "119-28"
    },
    "Abstract": {
      "AbstractText": [
        "Thirty-eight articles have been published on the association between elevated heart rate and mortality. After adjustment for other risk factors, most studies found an independent association between heart rate and all-cause and/or cardiovascular mortality. This relationship has been found to be generally weaker among females. The four studies performed in hypertensive patients found a positive association between heart rate and all-cause mortality or cardiovascular mortality. In spite of this evidence, elevated heart rate remains a neglected cardiovascular risk factor in both genders. The pathogenetic mechanisms connecting high heart rate, hypertension, atherosclerosis and cardiovascular events have also been elucidated in many studies. Several trials retrospectively showed the beneficial effect of cardiac-slowing drugs, such as beta-blockers and non-dihydropyridine calcium antagonists on mortality, notably in patients with coronary heart disease, or heart failure, but no published data are available in patients with hypertension free of coronary heart disease. Although it has not been proven in existing trials, it would seem reasonable to recommend in hypertensive subjects with heart rate > 80-85 b/min, antihypertensive agents that decrease the heart rate. The f-channel blockers, selective heart rate-lowering agents with no effect on blood pressure, could also be profitably used in hypertensive subjects with fast heart rate."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Dipartimento di Medicina Clinica e Sperimentale, Universit\u00e0 degli Studi, Padova. palatini@unipd.it"
          }
        ],
        "LastName": "Palatini",
        "ForeName": "Paolo",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "English Abstract",
      "Journal Article",
      "Review"
    ],
    "VernacularTitle": "La frequenza cardiaca: un fattore di rischio cardiovascolare che non pu\u00f2 essere ignorato."
  },
  "MedlineJournalInfo": {
    "Country": "Italy",
    "MedlineTA": "G Ital Cardiol (Rome)",
    "NlmUniqueID": "101263411",
    "ISSNLinking": "1827-6806"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Adrenergic beta-Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Arrhythmia Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antihypertensive Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Calcium Channel Blockers"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cardiovascular Agents"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "G Ital Cardiol (Rome). 2006 May;7(5):371-2; author reply 372-3",
      "PMID": "16752522"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Adrenergic beta-Antagonists"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Arrhythmia Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antihypertensive Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Calcium Channel Blockers"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Cardiovascular Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "mortality",
        "physiopathology"
      ],
      "DescriptorName": "Coronary Artery Disease"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [
        "drug therapy",
        "mortality",
        "physiopathology"
      ],
      "DescriptorName": "Heart Diseases"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Heart Rate"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "mortality",
        "physiopathology"
      ],
      "DescriptorName": "Hypertension"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Survival Rate"
    },
    {
      "QualifierName": [
        "mortality",
        "physiopathology"
      ],
      "DescriptorName": "Tachycardia"
    }
  ],
  "NumberOfReferences": "89"
}